Driving Lasting Impact That Moves Care Forward
Superficial venous disease continues to evolve, meaningful innovation must be grounded in evidence. Advancements in device technology are intrinsically linked to the generation of robust clinical data—data that supports confident clinical decision-making and improved patient outcomes. Sustained investment in research, education, and clinical evaluation reinforces trust in data-backed solutions and reflects the essential belief that innovation and evidence move forward together.
A Message From The President
“As we look to the future, we remain committed to continuous innovation in chronic venous disease. BD is invested in our customers, not just with our products but with the level of service we provide—from physician training to patient education.”
— Rima Alameddine
Worldwide President
BD Interventional-Peripheral Intervention
Investing in Clinical Evidence
Clinical outcomes are at the heart of everything we do. BD is actively investing in research and real-world experience to enable evidence-based decision making for the Venclose™ Catheter. In our latest post-market clinical study, we were able to conclude enrolling patients in the Great Saphenous Vein(GSV)/Small Saphenous Vein(SSV) cohort. This milestone reflects our ongoing commitment to generating real-world clinical evidence that will play a critical role in informing treatment decisions and will help deliver meaningful impact for patients.
Venclose™ digiRF™ System Post Market Study
Summary:,
A Post-Market, Multi-Center, Prospective, Interventional Study for Treatment of Chronic Venous Disease of the Great and Small Saphenous Veins and Incompetent Perforator Veins.
Design:
Provide clinical evidence to demonstrate the safety and effectiveness of the Venclose™ System.
GSV/SSV Cohort:
Products included Venclose™ RF Ablation Catheter and Venclose™ digiRF™ Generator
Lead Investigator/National PI: Erin Murphy, MD
Medical Monitor: Lowell Kabnick, MD
